Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't understand such an extreme pricing pressure in the US, are generics selling at a loss too ?
Really disappointing sales & cash from $321M to $308M, lost $13M just in a Q, that's a loss of $52M annualized
EPA Associated with Decreased Incidence of Alzheimer’s Dementia in the Oldest Old
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912244/
5. Conclusions
In conclusion, higher concentrations of EPA were associated with a lower incidence of AD dementia. In addition, we observed that higher concentrations of EPA were associated with a decreased risk for all-cause and AD dementia among APOE e4 non-carriers but not among APOE e4 carriers. Furthermore, a higher percentage distribution of EPA, DHA, and ALA was not associated with incidence all-cause and AD dementia. We recommend future studies to analyze both relative fatty acid profiles and absolute fatty acid concentrations. In addition, we encourage existing and new studies to prioritize their research on the oldest old and to investigate the interaction between PUFA and APOE e4.
Scientists hope that their research will encourage future clinical studies to determine the potential benefits of EPA in Alzheimer’s disease
https://nutrition.org/omega-3-fatty-acid-rich-diets-potential-benefits-in-lowering-risk-of-alzheimers-disease/
Relax, it's 30 business days (about 1 month and half) to get the notice + 180 days to cure + often appeal for another 180 days, it's the last of our problems
Some idiots read the 50 pence and 5 pence thing, it's just a legal term lol it's not the price of repurchase, unbelievable really, maybe the company will (and should) release a statement tomorrow
absolutely yes, net loss is not necessarily negative cash flow/burn
A small italian biotech firm, not a big pharma, just bought ICPT for about twice the market price, I think the same is going to happen to AMRN, it's trading at half the book value, unbelievably undervalued here
It's trading at half Book Value (Cash + Inventory), I am sorry but who the hell sells at this price ? I am buying more and more.
Someone just bought 2 million shares I think, volume went from 9M to 11M
AMRN has $1.80 a share of cash + inventory, don't tell me a Big Pharma wouldn't be interested in a buyout at least at the same price, $1.80, they get the company for free, selling at $1.10 is just plain stupid
If with all these problems they are still earning several millions a quarter + $313M cash + tons of inventory value, $1.80 book value (cash + inventory), people selling at $1.15 ? it's an easy +100% from here, at least, Europe + China sales coming soon with much higher pricing and margins
Key is EU Big 5 UK France Italy Germany Spain, basically same population of the USA
I guess you mean $89M overall worldwide for Q2, not just US revenue
Why US $89M Q2 from US $82M Q1 ? Q2 seems just slightly ahead of Q1, like 2% better
Is AMRN earning $15-18 million a year just from cash interest ? 5-6% rates on $300+ million
High interest rates is bad for companies with debts but bullish for companies with a ton of cash like Amarin
it's NOT a small royalty
1) AMRN sells Vascepa to Edding at a previously negotiated price
+
2) WHEN Edding will sell Vascepa to customers at a retail price AMRN ALSO gets a 15% royalty from that retail price
Overall revenue can be substantial and it's 100% pure net income, it's completely false that Edding is the only king in town
I think the Quarter will be very good, especially on costs cut and net income
but in the UK they are selling significantly less after Vascepa introduction, there is some overlap
Can anyone explain how Lovaza by GSK still sells 62-65K US weekly scripts while being vastly inferior to Vascepa ?
and GSK (Lovaza) already lost some UK market share to AMRN after just few months and it's going to worsen for GSK in the future and the same is obviously going to happen sooner or later in the rest of Europe, GSK should be interested in buying out AMRN at a fair price, don't you agree ? Why haven't they already at this super low price?
I added 6K today at $1.16, valuation is ridiculous, Going to add more if lower, I have 46K now, I feel a buyout coming soon, it's way too low
Biotechs do NOT trade at 1.3X revenue but AMRN does, it has major potential just by cutting useless costs, even without Europe and China sales
Denner should just buy more in the low $1s, have an average of $2-2.5 and sell the company at my target price of $2.80. Seems doable and realistic.
Higher interest rates will lead to more interest earned on the 300+ million of cash AMRN has
I think we'll see a positive surprise on costs reduction for the rest of the year and the stock will jump.
Right now we are trading at only 1.37x revenue/sales.
Goldman Sachs 44th Annual Global Healthcare Conference (June 12-15, 2023; Dana Point, California)
Jefferies Healthcare Conference (June 7-9, 2023; New York, New York)
Amarin will present at 2 upcoming investor conferences
well small caps are not skyrocketing at all actually, check Russell 2000 chart
well no, AMRN gets royalties for what Edding sells + also a previously negotiated price for delivering the product to Edding, check the original 2015 SEC filing for this 'China Agreement', AMRN has $370M inventory to unload which is cash when sold
and don't forget 1 keypoint, AMRN gets up to high teens % of the final price in China but it also sells the product at a negotiated price to Edding unloading the inventory.
Check the last 10Q, AMRN has about $370 million of inventory! (short term $226M + long term $144M)
It's the classic % for this kind of deal for any biotech, so there's nothing to complain about. In the USA Vascepa is sold for $100-105, in Europe it's much higher
UK for example it's £144 which is about $180, huge margins.
absolutely not, simply the agreement with Edding stands, there's no buyout of Edding (unless there's a second buyout agreement with Edding)
From Porter on SA "$15M upfront (in 2015) + $5M now + $149M in additional chinese future milestones + tiered double-digit % royalties up to high teens + inventory sales. Obviously it all depends on future real sales but the potential is huge yes, that's why the stock is overall very undervalued. it's trading as if Europe+China = zero sales, it's nonsense, especially for a small cap and a great drug. Let alone if new trials readouts will be good."
yes but it's pure net income without costs + AMRN also sells some inventory
are u joking ? that revenue is pure net income without costs, Edding covers all costs
2015 China Agreement: Under the agreement, Eddingpharm will be responsible for development and commercialization activities in the territory and associated expenses. Amarin will provide development assistance and be responsible for supplying finished, and later bulk, product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154.0 million. Eddingpharm will also pay Amarin tiered double-digit percentage royalties on net sales of Vascepa in the territory escalating to the high teens. Amarin will supply product to Eddingpharm under negotiated supply terms.
No problem. Do you know when the MITIGATE and BRAVE trial readouts are expected ? and How important do you think they are ? Thank You
Really ? Selling at $1.04 ? I'll buy 3x my position if it goes there
False, EddingPharma had to run a Phase 3 in China, it's in their own website
From Kevin Porter on SA: "Sarissa was founded in 2013 by Alex Denner, former senior managing director of Icahn Capital. Denner was the lead in Icahn’s investments in companies like Biogen, Amylin, Genzyme, MedImmune and ImClone and has sat on the boards of ImClone, Amylin, Biogen, Enzon and Adventrx. Denner has a doctoral degree in biotech. He also has a rare combination of analytical skills in this sector, activist skills, and experience. Sarissa has been involved with multiple health-care companies that have been acquired. Most notably, there is The Medicines Company, which was acquired by Novartis giving Sarissa a 138% return versus 16% for the S&P 500 over the same period. There is also Ariad Pharmaceuticals which was acquired by Takeda Pharmaceutical giving Sarissa a 529% return versus 32% for the S&P 500 over the same period."
Sounds very encouraging to me
Any of you has a link to check AMRN weekly TRXs ?
Thank you in advance
A company which doesn't let investors know anything (zero details!)
43 days after a private placement (which is fake) doesn't deserve to be listed even if it wasn't a complete fraud (and it is a complete fraud), it's just totally ridiculous